COYA

Coya Therapeutics, Inc. COYA

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,881 of 2,925

Why it scores 9Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$243.7K

Quarter to Jun 30

Net income

$-6.64M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$45.45M total
DME Capital Management, LP
$13.66M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$4.93M-0.3%
Alyeska Investment Group, L.P.
$4.68M0.0%
AIGH Capital Management LLC
$3.70M-35.2%
CM Management, LLC
$2.34M+6.7%
PRIVATE MANAGEMENT GROUP INC
$2.25M+4.1%
MARSHALL WACE, LLP
$1.46M+10.6%
GEODE CAPITAL MANAGEMENT, LLC
$1.34M-2.2%
RENAISSANCE TECHNOLOGIES LLC
$1.13M+85.6%
Prosight Management, LP
$994.5K-59.6%
DIMENSIONAL FUND ADVISORS LP
$913.0K+62.6%
VANGUARD FIDUCIARY TRUST CO
$757.9K-7.4%
JONES FINANCIAL COMPANIES LLLP
$610.0K+146.7%
BlackRock, Inc.
$599.1K+23.7%
PRELUDE CAPITAL MANAGEMENT, LLC
$592.8K0.0%
JBF Capital, Inc.
$585.0K0.0%
ROYAL BANK OF CANADA
$546.0K+597.5%
MORGAN STANLEY
$480.3K-4.2%
STATE STREET CORP
$466.9K0.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$356.9K+55.2%
NORTHERN TRUST CORP
$263.7K+11.5%
XTX Topco Ltd
$242.2K-12.5%
ADAR1 Capital Management, LLC
$239.3K0.0%
Long Corridor Asset Management Ltd
$226.8K0.0%
Cetera Investment Advisers
$198.9K+13.3%
See all 54 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/COYA

Earnings Per Share

13fpro.ai/company/COYA

Loading ratio trend…

COYA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Coya Therapeutics, Inc.'s annual filings on SEC EDGAR.

Coya Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$7.9M$-21.2M—
FY 2024$3.6M$-14.9M—
FY 2023$6.0M$-8.0M-131.7%
Source: COYA filings on SEC EDGAR →

COYA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Coya Therapeutics, Inc. (COYA): stock profile, AI score and financials

Coya Therapeutics, Inc. (COYA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores COYA at 9.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,881 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Coya Therapeutics, Inc. reports quarterly revenue of $243.7K, net income of $-6.6M. Top institutional holders of COYA by reported 13-F value include DME Capital Management, VANGUARD CAPITAL MANAGEMENT, Alyeska Investment Group, L.P., based on the most recent SEC filings. COYA trades on the Nasdaq exchange and files with the SEC under CIK 1835022. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coya Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1835022 →